# SARS-CoV-2 and COVID-19 Research **Type:** Topics **Canonical URL:** https://scholariq.org/topics/sars-cov-2-and-covid-19-research/ ## Facts | Field | Value | | --- | --- | | Description | This cluster of papers focuses on the research related to the coronavirus disease 2019 (COVID-19), including topics such as SARS-CoV-2, vaccine development, spike protein structure, antibody responses, viral mutations, and immune protection. The papers cover various aspects of the pandemic, from virus transmission to potential therapeutic targets. | | Domain | Health Sciences | | Field | Medicine | | OpenAlex ID | t10118 | | Works | 840 | ## Topic papers all Showing 15 of 840. - [A pneumonia outbreak associated with a new coronavirus of probable bat origin](https://scholariq.org/papers/a-pneumonia-outbreak-associated-with-a-new-coronavirus-of-probable-bat-origin/) - [Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia](https://scholariq.org/papers/early-transmission-dynamics-in-wuhan-china-of-novel-coronavirus-infected/) - [Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding](https://scholariq.org/papers/genomic-characterisation-and-epidemiology-of-2019-novel-coronavirus-implications/) - [WHO Declares COVID-19 a Pandemic.](https://scholariq.org/papers/who-declares-covid-19-a-pandemic/) - [Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro](https://scholariq.org/papers/remdesivir-and-chloroquine-effectively-inhibit-the-recently-emerged-novel/) - [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges](https://scholariq.org/papers/severe-acute-respiratory-syndrome-coronavirus-2-sars-cov-2-and-coronavirus/) - [Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy](https://scholariq.org/papers/baseline-characteristics-and-outcomes-of-1591-patients-infected-with-sars-cov-2/) - [A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19](https://scholariq.org/papers/a-trial-of-lopinavir-ritonavir-in-adults-hospitalized-with-severe-covid-19/) - [Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK](https://scholariq.org/papers/safety-and-efficacy-of-the-chadox1-ncov-19-vaccine-azd1222-against-sars-cov-2-an/) - [Temporal dynamics in viral shedding and transmissibility of COVID-19](https://scholariq.org/papers/temporal-dynamics-in-viral-shedding-and-transmissibility-of-covid-19-2/) - [Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China](https://scholariq.org/papers/cancer-patients-in-sars-cov-2-infection-a-nationwide-analysis-in-china/) - [Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial](https://scholariq.org/papers/remdesivir-in-adults-with-severe-covid-19-a-randomised-double-blind-placebo/) - [Extrapulmonary manifestations of COVID-19](https://scholariq.org/papers/extrapulmonary-manifestations-of-covid-19/) - [Emerging coronaviruses: Genome structure, replication, and pathogenesis](https://scholariq.org/papers/emerging-coronaviruses-genome-structure-replication-and-pathogenesis/) - [Antibody responses to SARS-CoV-2 in patients with COVID-19](https://scholariq.org/papers/antibody-responses-to-sars-cov-2-in-patients-with-covid-19/) ## Topic primary papers Showing 15 of 371. - [A pneumonia outbreak associated with a new coronavirus of probable bat origin](https://scholariq.org/papers/a-pneumonia-outbreak-associated-with-a-new-coronavirus-of-probable-bat-origin/) - [Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro](https://scholariq.org/papers/remdesivir-and-chloroquine-effectively-inhibit-the-recently-emerged-novel/) - [Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK](https://scholariq.org/papers/safety-and-efficacy-of-the-chadox1-ncov-19-vaccine-azd1222-against-sars-cov-2-an/) - [Antibody responses to SARS-CoV-2 in patients with COVID-19](https://scholariq.org/papers/antibody-responses-to-sars-cov-2-in-patients-with-covid-19/) - [Autoantibodies against type I IFNs in patients with life-threatening COVID-19](https://scholariq.org/papers/autoantibodies-against-type-i-ifns-in-patients-with-life-threatening-covid-19/) - [Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial](https://scholariq.org/papers/safety-and-immunogenicity-of-the-chadox1-ncov-19-vaccine-against-sars-cov-2-a/) - [SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues](https://scholariq.org/papers/sars-cov-2-receptor-ace2-is-an-interferon-stimulated-gene-in-human-airway/) - [Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods](https://scholariq.org/papers/analysis-of-therapeutic-targets-for-sars-cov-2-and-discovery-of-potential-drugs/) - [An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19](https://scholariq.org/papers/an-oral-sars-cov-2-m-sup-pro-sup-inhibitor-clinical-candidate-for-the-treatment/) - [Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis](https://scholariq.org/papers/development-and-clinical-application-of-a-rapid-igm-igg-combined-antibody-test/) - [Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003](https://scholariq.org/papers/epidemiology-and-cause-of-severe-acute-respiratory-syndrome-sars-in-guangdong/) - [The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity](https://scholariq.org/papers/the-impact-of-mutations-in-sars-cov-2-spike-on-viral-infectivity-and/) - [Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity](https://scholariq.org/papers/multiple-sars-cov-2-variants-escape-neutralization-by-vaccine-induced-humoral/) - [The COVID-19 pandemic](https://scholariq.org/papers/the-covid-19-pandemic/) - [BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection](https://scholariq.org/papers/ba-2-12-1-ba-4-and-ba-5-escape-antibodies-elicited-by-omicron-infection/) --- Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.